Printer Friendly

Lupin Pharmaceuticals.

BALTIMORE -- Lupin Pharmaceuticals, Inc. (LPI) is the U.S. wholly owned subsidiary of Lupin Ltd, which is among the top five pharmaceutical companies in India.

Headquartered in Baltimore, Lupin is dedicated to delivering high-quality, branded and generic medications trusted by health care professionals and patients.

Lupin is celebrating 10 years of success in the U.S. generics market. The company entered the U.S. generic pharmaceutical market in 2003 with the ANDA approval for cefuroxime axetil tablets.

Lupin's tremendous growth over the past 10 years can be attributed to a strong pipeline, solid customer relationships and flawless execution. Lupin is ranked fifth in terms of generic prescriptions dispensed, and reported year-over-year growth of 52% in fiscal 2013 with revenues of $548 million, up from $361 million in 2012.

Lupin has earned the trust of its customers after consistently delivering high-quality products at an affordable price. Its manufacturing capabilities have expanded over the past several years with the addition of numerous state-of-the-art facilities that ensures cutting-edge response time.

Executives stress that Lupin's ability to execute is what sets it apart from other generic manufactures.

The company's world-class facilities are built to manufacture and deliver a wide range of finished products to the U.S. market. All facilities are in constant compliance with quality, safety, environment standards as laid down by governments and regulators such as the U.S. Food and Drug Administration.

Lupin is one of the world's most vertically integrated global pharmaceutical companies and remains the leader in therapeutic categories such as cephalosporins, cardiovasculars and antituberculosis products.

Furthermore, Lupin develops its own API which enables the company to offer competitive pricing as well as manage its inventory.

The company is dedicated to continuing to expand its business; recently launching an oral contraceptive franchise, investing in research and development, and putting emphasis on a strong pipeline. Lupin is currently offering 60 generic products and more than 260 SKUs.

Lupin has 186 filed ANDA's and over 100 products in development. It is also the market share leader on the overwhelming majority of its products, including lisinopril and lisinopril hydrochlorothiazide tablets.

As of June, the company had 25 of its 52 products in the No. 1 position in terms of market share. Furthermore, 42 of those 52 products were in the top-three position.

As part of its community initiatives, Lupin is involved with multiple charitable organizations throughout the year, such as the Red Cross, the Salvation Army and United Way.

111 S. Calvert St., 21st Floor

Baltimore, Md. 21202

Key contact:

BOB HOFFMAN

Senior Vice President of Sales and Marketing, Generics Division

Phone: (866) 587-4617

Fax: (410) 576-2221

lupinpharmaceuticals.com

COPYRIGHT 2013 Racher Press, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:RX/Generic Drugs/Profiles
Publication:Chain Drug Review
Geographic Code:1U5MD
Date:Sep 30, 2013
Words:437
Previous Article:Breckenridge Pharmaceutical.
Next Article:Dr. Reddy's.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters